Review Article
Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
Table 2
Examples of ligands used for targeting of liposomal nanocarriers.
| Type of ligand | Ligand | Target | Reference(s) |
| Antibody | Anti-HER2 | HER2 receptor overexpressed by cancer cells | [34, 98, 100] | Anti-CD19 | CD19 overexpressed in B cell Lymphoma | [101] | Nucleosome-specific 2C5 mAb | Cancer cells surface-bound nucleosomes | [32, 102] |
| Protein | Transferrin | Transferrin receptor overexpressed by cancer cells | [36, 103] | Interleukin 13 (IL-13) | IL-13 receptor overexpressed in human gliomas | [104] |
| Peptide | Octreotide | Somatostatin receptor type 2 overexpressed by cancer cells | [105, 106] | LHRH-derived peptide | LHRH receptors overabundant on cancer cells | [107] | Arg-Gly-Asp (RGD) | αVβ3overexpressed by endothelial tumor cells | [108–110] |
| Small molecule | Folate | Folate receptor on cancer cells | [41, 111] | Estrone | Estrogen receptors overexpressed in ovarian and breast cancers | [42, 112] | Anisamide | Sigma receptors overexpressed by cancer cells | [113] |
| Sugar | Mannose | Dendritic cells and macrophages to induce an immune response | [114, 115] | Lactose | Asialoglycoprotein receptors overexpressed by hepatocellular carcinomas | [116] |
|
|
HER2: human epidermal growth factor receptor 2, mAb: monoclonal antibody, LHRH: luteinizing hormone releasing hormone.
|